Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049287 | 0.93 | DRD2 (0.52) | LMNADRD2ALDH1A1L3MBTL1CYP11B1 | |
| SCHEMBL31130047 | 0.93 | DRD2 (0.52) | LMNADRD2ALDH1A1L3MBTL1CYP11B1 | |
| SCHEMBL21178333 | 0.93 | DRD2 (0.52) | LMNADRD2ALDH1A1L3MBTL1CYP11B1 | |
| SCHEMBL5267967 | 0.93 | DRD2 (0.52) | LMNADRD2ALDH1A1L3MBTL1CYP11B1 | |
| SCHEMBL21183420 | 0.83 | LMNA (0.51) | LMNAALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL29372292 | 0.83 | TAS1R3 (0.48) | LMNAALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL16809869 | 0.82 | KMT2A (0.47) | LMNAALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL30444207 | 0.82 | KMT2A (0.47) | LMNAALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL4132933 | 0.82 | KMT2A (0.39) | LMNADRD2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL13936481 | 0.82 | KMT2A (0.39) | LMNADRD2ALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-02-20 | — | — | US | disclosed |
| EP-4491622-A2 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3740481-B9 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-10-23 | — | — | EP | disclosed |
| US-12065436-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-3740481-B1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117964573-A | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117924208-A | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-111757875-B | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11472796-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3740481-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836755-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-111757875-A | Dihydrobenzofuran and indene analogs as inotropic agents | 赛特凯恩蒂克公司 | 2020-10-09 | — | — | CN | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2019-08-22 | — | — | US | disclosed |
| WO-2019144041-A1 | DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119665-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
| US-10836755-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
| US-20210147399-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
| US-12065436-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
| US-11472796-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
| US-20190256504-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
| US-20250059173-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | LMNA 62/4885DRD2 4685/4885ALDH1A1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.